New Jersey’s state attorney general on Thursday said she had subpoenaed records from Amgen Inc. after accusations by two former employees that the biotech giant engaged in possibly improper marketing practices to boost sales of a top-selling psoriasis drug, the Los Angeles Times rerpots.

Early this week, Amgen was ordered to deliver “a comprehensive array” of documents and information concerning the marketing of Enbrel by Feb. 4, Atty. Gen. Anne Milgram said.

Her office said it was investigating whether Amgen promoted the treatment for uses not approved by the Food and Drug Administration and whether it violated patient privacy laws.

The Times reported last week that two former Amgen employees are seeking damages in arbitration proceedings, contending they were penalized for failing to go along with possibly improper marketing practices to boost Enbrel sales beyond the drug’s approved uses.

Amgen denies the allegations, saying they are without merit.

“Amgen will cooperate fully with the New Jersey attorney general in this investigation,” Amgen spokeswoman Mary Klem said.

Read the full L.A. Times story

. (registration required)